Translate page

English English
en Englishbg Bulgarianzh-CN Chinese (Simplified)hr Croatiancs Czechda Danishnl Dutchfi Finnishfr Frenchde Germanel Greekiw Hebrewhi Hindiid Indonesianit Italianja Japaneseko Koreanmk Macedonianpl Polishpt Portuguesero Romanianru Russiansr Serbiansk Slovaksl Slovenianes Spanishsv Swedishth Thaitr Turkishvi Vietnamese
× To share and enhance best practice management of CML, experts and interested clinicians can discuss difficult or interesting CML cases here. Physicians submit a brief history of the patient and the case for discussion (no more than 200 words) by posting it in this forum ("New Discussion" button below). Please include the country of origin.

Each clinical case will be forwarded to the expert clinical panel for a brief independent response. Consideration should be given to patient confidentiality. Details that are not critical to the case can be changed to preserve anonymity. Please consider including your email with the case. This will not be posted on the website, but is useful should further details be requested by the moderator.

As a full clinical history is necessary for accurate comment, cases and comments on the Forum are ONLY ACCEPTED FROM PHYSICIANS. If individual patients have a specific question we encourage them to contact their healthcare provider. General questions can be emailed to info@cml-foundation.org.

DISCLAIMER: The iCMLf does not recommend or endorse any specific tests, physicians, products, procedures, or opinions, and disclaims any representation, warranty, or guaranty as to the same. Reliance on any information provided in this Forum is solely at your own risk.

CML and breast cancer

More
9 years 6 months ago #1029 by 966076155
CML and breast cancer was created by 966076155
53 y-old lady with CML diagnosed February 2013. She achieved MMR on imatinib 400mg daily but lost it in September 2014, BCR-ABL/ABL being now 0.24% (IS). Last week was diagnosed with breast cancer still being evaluated. Any particular suggestions regarding TKI during chemotherapy she will likely need?
Manuel Abecasis
Quick Reply

Reply to 966076155

Your e-mail address will only be available to administators.
Go to editor..
Note: BBcode and smileys are still usable.
  • Giuseppe Saglio
  • Giuseppe Saglio's Avatar
9 years 6 months ago #1033 by Giuseppe Saglio
Replied by Giuseppe Saglio on topic CML and breast cancer
I would suggest to continue the therapy with imatinib 400 mg. I would switch to a second generation TKI only if CCyR is lost and after testing for the presence of BCR-ABL mutations as it is possible that the present loss of MMR is simply due to a lack of proper adherence, due to the concomitant discovery of breast cancer and maybe the thinking that breast cancer has been caused by imatinib. This patient needs a strong support, by doctors, family and psycologists. The intake of the imatinib therapy can be continued during the days of the chemotherapy cycles unless excessive gastrointestinal toxicity will develop. The imatinib can be discontinued only during the days of the post-chemo aplasia to avoid hematotoxicity and to facilitate recovery of the WBC and platelets. Multiple possible interactions between tamoxifen and imatinib have been described, as both are metabolised by CYP450. Other possible mechanisms of interaction have been reported. In this case the imatinib dosage should be modulated based on the response and on the side effects observed and (if possible) by imatinib blood level testing.
Quick Reply

Reply to Giuseppe Saglio

Your e-mail address will only be available to administators.
Go to editor..
Note: BBcode and smileys are still usable.
  • tlh1g
  • tlh1g's Avatar
9 years 6 months ago - 9 years 6 months ago #1034 by tlh1g
Replied by tlh1g on topic CML and breast cancer
From CML point of view check compliance and a mutation screen.

For breast cancer continue imatinib 400mg but be on the look out for greater degree of neutropenia with each cycle of chemo - use G-CSF if required to support neutrophil counts. If severe neutropenia may need to stop imatinib temporarily (7 days) at expected neutropenia.

Tessa Holyoake
Last edit: 9 years 6 months ago by Melissa Davis-Bishop.
Quick Reply

Reply to tlh1g

Your e-mail address will only be available to administators.
Go to editor..
Note: BBcode and smileys are still usable.
  • jeff lipton
  • jeff lipton's Avatar
9 years 6 months ago #1035 by jeff lipton
Replied by jeff lipton on topic CML and breast cancer
I would continue TKI at full dose. I have now done this with chemotherapy in a couple of dozen cases and only in one case of bladder cancer, did the drug have to stop. Remember, it should be active only against CML clones, not the normal clones in a patient who has been on it for a while and thus is not likely going to have an impact on the normal stem cells which will be affected by the chemo. Unless there is a potential interaction between the chemo and the TKI you should be fine.
Check for all the reasons for loss of TKI response. If a switch is necessary, you could make a theoretical argument about using dasatinib because of the src activity which may have some impact on the breast cancer as well.
Quick Reply

Reply to jeff lipton

Your e-mail address will only be available to administators.
Go to editor..
Note: BBcode and smileys are still usable.
Moderators: Nicola, arlene